NCT02324153View on ClinicalTrials.gov

Ramelteon in the Prevention of Post-operative Delirium

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 24, 2017

Primary Completion Date

June 26, 2019

Study Completion Date

June 26, 2019

Conditions
DeliriumDelirium, Dementia, Amnestic, Cognitive DisordersDelayed Emergence From AnesthesiaCognitive Disorders
Interventions
DRUG

Ramelteon

1 pre-operative and 2 nightly postoperative doses of Ramelteon/placebo will be administered

DRUG

Microcrystalline Cellulose

Placebo Comparator

DRUG

Riboflavin 100 mg

Riboflavin will be added to both placebo and active intervention capsules in order to track adherence to dose while taken as an outpatient (i.e. only the first preoperative dose)

Trial Locations (1)

21224

Johns Hopkins Bayview Medical Center, Baltimore

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Johns Hopkins University

OTHER

NCT02324153 - Ramelteon in the Prevention of Post-operative Delirium | Biotech Hunter | Biotech Hunter